Sirtuins (SIRTs) are nicotinamide adenine dinucleotide (NAD + )-dependent protein deacetylases, which regulate important biological processes ranging from apoptosis, age-associated pathophysiologies, adipocyte and muscle differentiation, and energy expenditure to gluconeogenesis. Very recently, sirtuin 5 (SIRT5) has received considerable attention due to that it was found to have weak deacetylase activity but strong desuccinylase, demalonylase and deglutarylase activities, and it was also found to be associated with several human diseases such as cancer, Alzheimer's disease, and Parkinson's disease. In this review, we for the first time summarized the structure characteristics, known peptide and small-molecule inhibitors of SIRT5, extracted some clues from current available information and introduced some feasible, practical in silico methods, which might be useful in further efforts to develop new SIRT5 inhibitors.
INTRODUCTION
Histone deacetylases (HDACs) are a type of enzymes that remove acetyl groups from ɛ-N-acetyl-lysine amino groups on histones and various non-histone proteins. To date, four classes of histone deacetylases have been identified in humans (Figure 1 ) (Hirschey, 2011; Jing and Lin, 2015) . Class I, II, and IV HDACs are zinc 2+ -dependent deacetylases, while class III is nicotinamide adenine dinucleotide (NAD + )-dependent deacetylases. NAD + -dependent deacetylases are also termed sirtuins (SIRTs) due to their homology to the yeast silent information regulator 2 (SIR2). There *Corresponding author (email: liguobo@scu.edu.cn) **Corresponding author (email: chenxianggui@tom.com) are seven homologues of sirtuins in human, SIRT1 through SIRT7. SIRT1-3 have been well studied for decades (Bell and Guarente, 2011; Donmez and Outeiro, 2013; Mellini et al., 2015) , whereas SIRT4-7 have received relatively little attention until recently. SIRT5 has become an active topic of research towards its biological and physiological functions (Du et al., 2011; Nishida et al., 2015; Polletta et al., 2015; Tan et al., 2014) . Several studies have demonstrated that SIRT5 actually has relatively weak deacetylase activity comparing with other sirtuins. In contrast, SIRT5 has robust desuccinylation, demalonylation and deglutarylation activities in vitro and in vivo, ∼1,000-fold higher catalytic efficiency than deacetylation activity . Many studies also revealed that SIRT5 plays crucial roles in the regulation of ammonia detoxification (Nakagawa et al., 2009; Polletta , 2015) , fatty acid oxidation (Park et al., 2013; Zhang et al., 2015) , cellular respiration (Li et al., 2015a; Park et al., 2013) , ketone body formation (Rardin et al., 2013) , and reactive oxygen species (ROS) management , and disregulation or uncontrolled activation of SIRT5 can cause several human diseases, for instance cancer, Alzheimer's disease, and Parkinson's disease (Kumar and Lombard, 2015; Lai et al., 2013; Liu et al., 2015; Lu et al., 2014; Parihar et al., 2015) .
Currently, the biological functions and therapeutic possibilities of SIRT5 have been well documented (Du et al., 2011; Nakagawa et al., 2009; Rardin et al., 2013; Yang et al., 2015) . In this review, we present a summary of characteristics of SIRT5 structure and inhibitors, and more specifically extract some clues from current available information and suggest some useful methods for the design of new SIRT5 inhibitors, which were expected to be helpful for developing new SIRT5 inhibitors for the treatment of related diseases.
STRUCTURE CHARACTERISTICS OF SIRT5
Several high-resolution crystal structures of SIRT5 have been reported recently (Du et al., 2011; Roessler et al., 2014; Schuetz et al., 2007; Szczepankiewicz et al., 2012; Zhou et al., 2012) , which provide valuable clues for the bio-functional mechanism research as well as inhibitor design. From available crystal structures, we can see that SIRT5 consists of 14 α helices and 9 β strands, which organized two main domains: zinc -binding domain contains a small, three-stranded antiparallel β sheet (β4, β5, and β6) and five small α helices (α3, α4, α5, α8, and α9). The zinc ion, which is coordinated to four cysteine amino residues (including Cys166, Cys169, Cys207, and Cys212), is the key factor to keep the three-stranded antiparallel β sheet stable (Figure 2 ). The Rossmann fold domain consists of 6 parallel β strands (β1, β2, β3, β7, β8 and β9) that form a β sheet center, and 9 helices (α1, α2, α6, α7, α10, α11, α12, α13 and α14) that surround the β sheet center. The cleft between these two domains is connected by several loops, which actually forms the catalytic site, including substrate binding site and NAD + binding site (Figure 2 ). The loop S, which connects the strand β6 of the zinc binding domain and the helix α10 of Rossmann fold domain, is very important for substrate binding. The loop N, which connects the helix α3 of the zinc 2+ binding domain and the α2 helix of the Rossmann fold domain, is important for NAD + binding (Figure 2 ). By comparing crystal structures of SIRT5 with other sirtuins including SIRT1 (Davenport et al., 2014) , SIRT2 (Moniot et al., 2013) , SIRT3 (Jin et al., 2009) , and SIRT6 , SIRT5 was observed to have a similar overall domain organization and fold to the structures of SIRT1, SIRT2, and SIRT3 ( Figure 3A ), but a different domain fold with SIRT6 especially in zinc 2+ binding domain and catalytic site ( Figure  3B ). As shown in Figure 3A , the catalytic sites of SIRT5, SIRT1, SIRT2, and SIRT3 superimpose very closely, and the residues around the catalytic site are relatively conserved. For example, the residues Phe223, Leu227, and Val254 in SIRT5 can be found at the corresponding position in SIRT1, SIRT2, and SIRT3 ( Figure 3A ). These three hydrophobic residues form a small triangle and define the entrance for the acyl-lysine group of the substrate. Especially, Phe223 seems to be a gate keeper, which can block big motifs enter the substrate binding site and make way for kind of linear residues such as lysine, hence dramatically maintaining the substrate selec- tivity. Another important residue Phe70 is also highly conserved within sirtuin family ( Figure 3A ). Phe70 was found to have two different orientations, like a switch residue. When the benzene ring of Phe70 interacts with the N-ribose ring via pi-hydrophobic interactions, Phe70 can stabilize the NAD + or intermediate, but whilst Phe70 is perpendicular to the ribosyl ring of NAD + , it seems to favor nicotinamide escape. There also exist many other conserved residues in sirtuin members ( Figure 3A ), which make them possess similar biological functions. In contrast, an obvious difference between the domain folds of SIRT5 and SIRT6 was observed ( Figure 3B ); SIRT6 does not have small α helices in the zinc 2+ -binding domain, which is the conserved structure characteristic for SIRT1, SIRT2, SIRT3 and SIRT5 ( Figure 3A) . Besides, SIRT6 possesses a specific loop X located outside of the binding site leading to a different active site compared with SIRT5, which is an important factor contributing to its specific substrate profile ( Figure 3B ).
Structural differences between sirtuins can be observed in the variable amino-and carboxy-terminal extensions ( Figure  3A ), where they may regulate their subcellular localizations and catalytic activities, and keep their own specific biological and physiological functions. Even though in core catalytic domain, SIRT5 possesses its own specific residues. For example, the two non-hydrophobic residues Tyr102 and Arg105, located in the deep end of substrate binding pocket, are exclusive to SIRT5 ( Figure 3A) , which are likely to specifically recognize negatively charged acyl-lysine groups (i.e. succinyl, demalonyl, and glutaryl). SIRT5 has a small residue Ala86 (Phenylalanine residue is in the corresponding position to SIRT1, SIRT2, and SIRT3, see Figure 3A ), which make SIRT5 harbor a larger acyl-lysine binding pocket than other sirtuins. Due to these specific structural characteristics, SIRT5 is the only sirtuin member to date demonstrated to have efficient demalonylase and desuccinylase activity (Du et al., 2011) .
To further understand how substrate and NAD + bind and the specificity of SIRT5, one crystal structure reported recently by Du et al. (PDB code: 3RIY) was taken for example (Du et al., 2011) . This is a ternary crystal structure, in which co-factor NAD + and succinyl-H3K9 substrate peptide bind. As shown in Figure 4 , substrate peptide and NAD + both locate in the interspace between zinc 2+ binding domain and Rossmann fold domain. Those residues including Phe70, Arg71, Gln140, Asn141, and Asp143, are very important for NAD + binding (Figure 4) . The Gln140 and Asn141 hold the binding of NAD + ribose part, and Asp143 directly interacts with nicotinamide part. More interestingly, the flexible residue Phe70 plays a crucial role in keep NAD + binding/unbinding, like a switch residue (Figure 4) . For substrate peptide binding, the important residues include His158, Phe223, Try102 and Arg105 (Figure 4 ). As described above, Tyr102 and Arg105 are the unique residues for SIRT5, which form hydrogen-bonding and ionic-bonding interactions with the carboxyl of succinyl-lysine substrate. Besides, we observed that the succinyl moiety of substrate peptide is positioned to make direct interactions with ribose motif of NAD + .
SIRT5 INHIBITORS
SIRT5 is known to be involved in cellular metabolism and metabolic energy homeostasis by its various protein substr- Yang, L., et al. Sci China Life Sci March (2017) Vol. 60 No. 3 Figure 4 An example of the succinyl-K9 peptide-NAD + ternary crystal structure (PDB code: 3RIY).
strates. The possibilities of targeting SIRT5 are beginning to be more extensively investigated with aim of providing new strategies for the treatment of related diseases, since SIRT5 was demonstrated to be activation/over-expression in several human diseases (i.e. cancer). For example, an integrated genomic analyses of ovarian carcinoma revealed that region encompassing the SIRT5 locus was amplified 30% in ovarian carcinoma (Network, 2011) . Very recently, Lu et al. found that SIRT5 is over-expressed in advanced non-small cell lung cancer (NSCLC), and knock-down of SIRT5 could repress the growth rate of NSCLC cell lines (Lu et al., 2014) . Lutz and his colleagues revealed that the expression of SIRT5 was increased during the progression of Alzheimer's disease in contrast to SIRT1 and SIRT (Lutz et al., 2014) . Glorioso et al. found that SIRT5 might be an important risk factor contributing to mitochondrial dysfunction-related diseases including Parkinson's disease through accelerating molecular aging of disease-related genes (Glorioso et al., 2011) . Discovery of SIRT5 inhibitors is likely to be an attractive area for treatment of associated diseases. The reported peptide and small-molecule inhibitors of SIRT5 are hence summarized in following section.
Peptide inhibitors
Peptide inhibitors usually can be used as not only chemical probes for molecular mechanism research but also good starting points for small-molecule inhibitor design. Inspired by the fact that thioacetyl peptides can inhibit the deacetylase activities of sirtuins via forming a stable covalent intermediate, He and co-workers synthesized the first SIRT5-specific inhibitor, namely histone H3K9 thiosuccinyl peptide (H3K9TSu, Figure 5 ), which is a competitive inhibitor with an IC50 value of 5 μmol L -1 . Subsequent structure-activity relationship (SAR) study showed that the peptide inhibitors with a thiosuccinyl-lysine residue at the C-terminus or N-terminus were less potent than that in the middle, and the longer thiosuccinyl peptide seems to have better inhibitory activity against SIRT5. Another study by Roessler et (Zang et al., 2015) . More interestingly, peptide inhibitors containing this warhead seem to circumvent the cytotoxicity problem associated with the inhibitors bearing the N ɛ -thioacyl-lysines.
Small molecule inhibitors
Given the fact that peptide inhibitors generally suffered from limited pharmacological relevance due to their size, limited biostability and poor membrane permeability, it is desirable to develop small-molecule SIRT5 inhibitors for characterizing the physiological function and therapeutic potential. Suramin is one of the very few known pharmacological SIRT5 smallmolecule inhibitors, which inhibits SIRT5 non-specifically at submicromolar level by blocking substrate and NAD + binding (Figure 6 ) (Gertz and Steegborn, 2010; Schuetz et al., 2007) . Maurer et al. using their own established method tested several known SIRT1-3 small-molecule inhibitors and co-products of the reaction of deacetylation and deacylation, nicotinamide against SIRT5, and found that sirtinol, cambinol and nicotinamide ( Figure 6 ) can inhibit SIRT5 at submicromolar level (Maurer et al., 2012) . Similarly, Suenkel's group has found that GW5074 (Figure 6 ) has considerable inhibitory activity to SIRT5's desuccinylation activity (85% inhibitory activity at 100 μmol L -1 ), but it has weaker effects to SIRT5 deacetylation (Suenkel et al., 2013) . Different from above studies, Maurer et al. identified thiobarbiturate-containing compound 9 and compound 10 ( Figure 6 ) as new inhibitors by direct screening, which have low μmol L -1 potency against SIRT5 (Maurer et al., 2012) . These inhibitors should be good starting points to develop new SIRT5 inhibitors.
CLUES AND METHODS FOR THE DESIGN OF NEW SIRT5 INHIBITORS
As mentioned above, SIRT5 is a potential drug target, but few SIRT5 inhibitors have been reported so far. It is presently desirable to discover new SIRT5 inhibitors for molecular mechanism research and drug discovery. Some clues extracted from available crystal structures and inhibitors of SIRT5 as well as those of other sirtuins, and practical computer-aided drug design (CADD) methods given in following section should be useful in further efforts to develop new SIRT5 inhibitors. The NAD + binding site and substrate binding site are currently two main binding pockets for SIRT5 inhibitors. For NAD + binding site, those attempts including identifying NAD + analogues and competitive inhibitors could be an effective strategy to inhibit SIRT5. However, due to that a large number of human enzymes use NAD + as a co-substrate, the inhibitors against NAD + binding site may result in concerns of their target selectivity. In contrast, to discover selective SIRT5 inhibitors via targeting substrate binding site is likely to be a recommended strategy since some specific residues (i.e. Tyr102, Arg105, and Ala86) form a relatively large, specific substrate binding pocket (for details please see structure characteristics of SIRT5).
According to available substrate-SIRT5 complex structures, three important features for substrate binding concluded here could be useful for designing inhibitors targeting substrate binding pocket. First, two specific non-hydrophobic residues, Arg105 and Tyr102, in the deep end of substrate binding pocket interact with the succinyl-lysine group of substrate via hydrogen-bonding and electrostatic interactions (Figure 4 ), indicating that negatively charged groups (i.e. carboxyl and tetrazole) or polar chemical groups (i.e. sulfonamide and isoxazol-3-ol) could be preferred chemical moieties to occupy this kind of pocket. Second, Phe223 in loop S is likely to be a gate keeper to restrict large fragments to go into the deep end of substrate binding pocket, suggesting that it is desirable to design some rigid, linear chemical moieties or small aromatic rings as linkage scaffolds with key pharmacophore features. Third, three hydrophobic residues including Leu227, Val254, Phe223 form a triangle-shaped entrance for substrate binding, which suggests that small-molecule compounds with similar triangle shapes might perfectly fit with the substrate binding site. Besides, some clues also could be obtained from SIRT5's neighbor family members, even though they have structural differences. For example, Rumpf et al. recently found a new binding pocket for SIRT2 induced by a selective inhibitor, termed SirReal2 (Rumpf et al., 2015) . This study might inspire people to search novel SIRT5 inhibitors targeting other possible unexploited binding pockets.
Currently, a number of well-established CADD methods (Ekins et al., 2007; Li et al., 2015c) could be very useful in designing new SIRT5-specific inhibitors. For example, according to available substrate-SIRT5 crystal structures, three dimensional (3D) shape-based methods such as ROCS, ShaEP and Phase Shape would be effective tools to identify small-molecule compounds having similar shape with SIRT5 substrate. Pharmacophore-based methods (Yang et al., 2012; Yang, 2010) can be used to generate a reasonable pharmacophore model from substrate-SIRT5 structures to search for potential inhibitors. Molecular docking and molecular dynamics methods also are very useful in lead discovery and lead optimization. Recently, some combined hierarchical in silico methods were established, which could avoid inherent shortcomings of each individual method and capitalize on their mutual strengths Ren et al., 2011) . A hierarchical virtual screening method described in following might be a useful method to identify new SIRT5 inhibitors. The first step is to establish a carboxyl/carboxyl isostere focused chemical library for SIRT5 since carboxyl/carboxyl isostere groups may form interactions with the specific residues Arg105 and Tyr102. The second step is to use molecular docking to search possible binding poses for the established focused chemical library. The third step is to use interaction fingerprints-based methods or pharmacophore-based to filter the docking poses (de Graaf et al., 2011; Muthas et al., 2008) . The final step is to use rescoring methods for example molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) (Suri and Naik, 2015) and ID-Score to predict the binding affinity for providing information to help select potential hit compounds. The use of these multiple, complementary methods could increase the success rate of identifying new SIRT5 inhibitors. In addition to above described methods, structure-based or pharmacophore-based de novo design methods (Schneider and Fechner, 2005; Talamas et al., 2013) as well as scaffold hopping or substitute modification methods (Li et al., 2015b; Mauser and Guba, 2008) are worth to use because these methods might be able to discover novel SIRT5 inhibitors with novel chemical scaffolds.
SUMMARY
SIRT5 is an attractive enzyme for mechanism research since it not only has deacetylase activity but also has strong demalonylase, desuccinylase and deglutarylase activities. SIRT5 is also considered as a potential molecular target for treatment of several human diseases. In this review, we summarized the structural characteristics of SIRT5 and its structural differences to other sirtuins, and highlighted the detailed, specific structural binding of SIRT5 substrates. In addition, we gave a summary of currently known peptide and small-molecule SIRT5 inhibitors. Moreover, we extracted some clues from current available information and gave some feasible, practical in silico methods for SIRT5 inhibitor design. We hope this review can help people understand SIRT5 structure characteristics and provide useful information for further efforts to develop new SIRT5 inhibitors for related molecular mechanism research as well as drug discovery & development.
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